p70 Ribosomal protein S6 kinase (Rps6kb1): an update

被引:73
作者
Bahrami-B, Farnaz [1 ]
Ataie-Kachoie, Parvin [2 ]
Pourgholami, Mohammad H. [2 ]
Morris, David L. [1 ]
机构
[1] Univ New S Wales, Cancer Res Labs, Dept Surg, St George & Sutherland Clin Sch, Sydney, NSW, Australia
[2] St George Hosp, Dept Surg, Sydney, NSW 2217, Australia
关键词
EXTENDS LIFE-SPAN; MAMMALIAN TARGET; TUBEROUS SCLEROSIS; PHOSPHORYLATION SITE; INSULIN-RESISTANCE; SIGNALING PATHWAY; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CELL-GROWTH; MTOR;
D O I
10.1136/jclinpath-2014-202560
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
The Rps6kb1 gene encodes the 70 kDa ribosomal protein S6 kinase (p70S6K), which is a serine/threonine kinase regulated by phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. p70S6K plays a crucial role in controlling cell cycle, growth and survival. The PI3K/mTOR signalling pathway is one of the major mechanisms for controlling cell survival, proliferation and metabolism and is the central regulator of translation of some components of protein synthesis system. Upon activation, this kinase phosphorylates S6 protein of ribosomal subunit 40S resulting in selective translation of unique family of mRNAs that contain oligopyrimidine tract on 5' transcriptional site (5'TOP). 5'TOP mRNAs are coding the components of translational apparatus including ribosomal proteins and elongation factors. Due to the role of p70S6K in protein synthesis and also its involvement in a variety of human diseases ranging from diabetes and obesity to cancer, p70S6K is now being considered as a new therapeutic target for drug development. Furthermore, p70S6K acts as a biomarker for response to immunosuppressant as well as anticancer effects of inhibitors of the mTOR. Because of the narrow therapeutic index of mTOR inhibitors, drug monitoring is essential, and this is usually done by measuring blood drug levels, therapeutic response and drug-induced adverse effects. Recent studies have suggested that plasma p70S6K is a reliable index for the monitoring of patient response to mTOR inhibitors. Therefore, a better understanding of p70S6K and its role in various pathological conditions could enable the development of strategies to aid diagnosis, prognosis and treatment schedules.
引用
收藏
页码:1019 / 1025
页数:7
相关论文
共 110 条
[51]
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours [J].
Hollebecque, Antoine ;
Houede, Nadine ;
Cohen, Ezra E. W. ;
Massard, Christophe ;
Italiano, Antoine ;
Westwood, Paul ;
Bumgardner, William ;
Miller, Joel ;
Brail, Les H. ;
Benhadji, Karim A. ;
Soria, Jean-Charles .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) :876-884
[52]
Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase [J].
Holz, MK ;
Blenis, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (28) :26089-26093
[53]
The expression of poly(A)-binding protein gene is translationally regulated in a growth-dependent fashion through a 5′-terminal oligopyrimidine tract motif [J].
Hornstein, E ;
Git, A ;
Braunstein, I ;
Avni, D ;
Meyuhas, O .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (03) :1708-1714
[54]
Exploiting p70 S6 kinase as a target for ovarian cancer [J].
Ip, Carman K. M. ;
Wong, Alice S. T. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (06) :619-630
[55]
Overexpression of S6 Kinase 1 in Brain Tumours Is Associated with Induction of Hypoxia-Responsive Genes and Predicts Patients' Survival [J].
Ismail, Heba M. S. .
JOURNAL OF ONCOLOGY, 2012, 2012
[56]
IDENTIFICATION AND CHARACTERIZATION OF A MITOGEN-ACTIVATED S6 KINASE [J].
JENO, P ;
BALLOU, LM ;
NOVAKHOFER, I ;
THOMAS, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (02) :406-410
[57]
Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: Possible involvement in obesity-linked insulin resistance [J].
Khamzina, L ;
Veilleux, A ;
Bergeron, S ;
Marette, A .
ENDOCRINOLOGY, 2005, 146 (03) :1473-1481
[58]
Kim SH, 2009, ANTICANCER RES, V29, P1143
[59]
AMP kinase (PRKAA1) [J].
Krishan, Sukriti ;
Richardson, Des R. ;
Sahni, Sumit .
JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (09) :758-763
[60]
LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non- mTOR-dependent mechanisms. [J].
Kristof, AS ;
Pacheco-Rodriguez, G ;
Schremmer, B ;
Moss, J .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (03) :1134-1143